[Form 4] Staar Surgical Co Insider Trading Activity

Rhea-AI Filing Summary

STAAR Surgical Co. (STAA) Form 4 filing: Director Lilian Y. Zhou, Chair of the Capital Stewardship Committee, was granted 4,363 non-qualified stock options on 25 June 2025 under the company’s annual non-employee director equity program. The options carry an exercise price of $16.72 and expire 24 June 2035. Vesting occurs quarterly in four equal tranches—25 September 2025, 25 December 2025, 25 March 2026, and 25 June 2026—resulting in full vesting within one year. Following the grant, Zhou beneficially owns 4,363 derivative securities directly. No sales, exercises, or additional equity transactions were reported. The filing represents routine director compensation and does not indicate changes in ownership of outstanding common shares.

Insights

Financial Analyst

TL;DR: Routine director option grant; immaterial to STAA valuation; neutral signal for investors.

The 4,363-option award at $16.72 aligns with STAAR Surgical’s standard non-employee director compensation and vests within 12 months. The total face value, even when fully in-the-money, represents a negligible percentage of STAA’s outstanding shares and market capitalization. Because no open-market purchases or sales occurred, the filing is largely administrative, offering limited insight into management’s view of valuation or near-term fundamentals. Investors should view the disclosure as neutral and focus on upcoming earnings and product pipeline developments for material catalysts.

Corporate Governance Expert

TL;DR: Properly disclosed equity grant reflects sound governance; no red flags detected.

The timely Form 4 filing illustrates STAAR Surgical’s adherence to Section 16 reporting requirements. Granting options that vest quarterly over one year promotes director alignment without encouraging excessive risk-taking. The use of a 10b5-1 compliant structure further mitigates insider-trading concerns. From a governance perspective, the transaction is routine, well-documented, and poses no material dilution risk.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhou Lilian Yansheng

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Options	$16.72	06/25/2025		A		4,363		(1)	06/24/2035	Common Stock	4,363	$0	4,363	D

Explanation of Responses:

1. Award of stock options granted to the Reporting Person on June 25, 2025. These stock options will vest as to 1/4 of the shares subject to the award on a quarterly basis on each of September 25, 2025, December 25, 2025, March 25, 2026, and June 25, 2026.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 25, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for service as the Chair of the Capital Stewardship Committee.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Lilian Y. Zhou	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STAAR Surgical (STAA) disclose in the latest Form 4?

STAA reported granting 4,363 stock options to Director Lilian Y. Zhou on 25 June 2025 at an exercise price of $16.72.

How do the granted options vest for Director Lilian Zhou?

The options vest 25% each quarter on 25 Sep 2025, 25 Dec 2025, 25 Mar 2026, and 25 Jun 2026.

When do the newly granted STAA options expire?

The expiration date is 24 June 2035—10 years from the grant date.

Did the Form 4 include any stock sales or purchases?

No. The filing only records an option grant; there were no open-market transactions.

Is the transaction likely to materially impact STAA’s share count?

No. 4,363 options represent an immaterial fraction of STAA’s total shares outstanding.